The stock of Emergent Biosolutions Inc (NYSE:EBS) is a huge mover today! About 524,835 shares traded hands or 30.32% up from the average. Emergent Biosolutions Inc (NYSE:EBS) has declined 28.61% since April 27, 2016 and is downtrending. It has underperformed by 33.83% the S&P500.
The move comes after 5 months negative chart setup for the $1.08B company. It was reported on Nov, 30 by Barchart.com. We have $26.36 PT which if reached, will make NYSE:EBS worth $32.40M less.
Analysts await Emergent Biosolutions Inc (NYSE:EBS) to report earnings on February, 23. They expect $0.60 EPS, down 23.08% or $0.18 from last year’s $0.78 per share. EBS’s profit will be $23.84 million for 11.33 P/E if the $0.60 EPS becomes a reality. After $0.58 actual EPS reported by Emergent Biosolutions Inc for the previous quarter, Wall Street now forecasts 3.45% EPS growth.
Emergent Biosolutions Inc (NYSE:EBS) Ratings Coverage
Out of 3 analysts covering Emergent Biosolutions (NYSE:EBS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Emergent Biosolutions has been the topic of 5 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating given on Friday, February 19 by Wells Fargo. The firm has “Hold” rating given on Monday, August 10 by Zacks. The firm has “Buy” rating by Singular Research given on Tuesday, June 28. Singular Research initiated Emergent Biosolutions Inc (NYSE:EBS) rating on Monday, March 28. Singular Research has “Buy” rating and $44 price target. As per Friday, April 15, the company rating was initiated by Chardan Capital Markets.
According to Zacks Investment Research, “EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops, manufactures and commercializes vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Their products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Their marketed product, BioThraxÂ® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection.”
Insitutional Activity: The institutional sentiment decreased to 1.21 in 2016 Q2. Its down 0.35, from 1.56 in 2016Q1. The ratio fall, as 25 funds sold all Emergent Biosolutions Inc shares owned while 55 reduced positions. 35 funds bought stakes while 90 increased positions. They now own 35.17 million shares or 5.50% more from 33.34 million shares in 2016Q1.
Nationwide Fund has 43,643 shares for 0.01% of their US portfolio. Smith Asset Mgmt Group Lp holds 0.01% of its portfolio in Emergent Biosolutions Inc (NYSE:EBS) for 7,392 shares. Metropolitan Life Ins Co Ny accumulated 23,280 shares or 0% of the stock. Numeric Invsts Lc accumulated 0.1% or 382,817 shares. The Colorado-based Pub Employees Retirement Association Of Colorado has invested 0.03% in Emergent Biosolutions Inc (NYSE:EBS). Systematic Fincl Management L P, a New Jersey-based fund reported 58,775 shares. Pine River Mngmt Limited Partnership last reported 0.09% of its portfolio in the stock. Architects Inc, a New Jersey-based fund reported 300 shares. Meeder Asset Inc has 0.05% invested in the company for 19,056 shares. Allianz Asset Mngmt Ag has 93,487 shares for 0% of their US portfolio. Rmb Capital Mgmt Ltd Liability Company reported 107,577 shares or 0.16% of all its holdings. Panagora Asset Mgmt has 0.02% invested in the company for 137,069 shares. Royal London Asset Mngmt last reported 32,059 shares in the company. Axiom Investors Lc De has invested 0.04% of its portfolio in Emergent Biosolutions Inc (NYSE:EBS). The Pennsylvania-based Wharton Business Grp Limited Liability has invested 0.04% in Emergent Biosolutions Inc (NYSE:EBS).
Insider Transactions: Since June 1, 2016, the stock had 0 buys, and 1 sale for $207,364 net activity. 4,700 shares with value of $207,364 were sold by JOULWAN GEORGE A on Monday, June 6. Shares for $380,494 were sold by Abdun-Nabi Daniel.
More notable recent Emergent Biosolutions Inc (NYSE:EBS) news were published by: Fool.com which released: “Emergent Biosolutions Inc Slimmed Down, Waiting on Contract” on November 10, 2016, also Fool.com with their article: “Why Emergent BioSolutions Inc. Procured a Lower Price Today” published on June 22, 2016, Fool.com published: “Why Emergent Biosolutions Inc Surged Higher Today” on September 30, 2016. More interesting news about Emergent Biosolutions Inc (NYSE:EBS) were released by: Forbes.com and their article: “Emergent BioSolutions Is Oversold” published on June 27, 2016 as well as Fool.com‘s news article titled: “Emergent BioSolutions Inc. Asks for Patience” with publication date: August 11, 2016.
EBS Company Profile
Emergent BioSolutions Inc., incorporated on December 19, 2003, is a biopharmaceutical firm that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Firm develops, makes and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID). It also develops and commercializes therapeutics, and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. The Company’s two operating divisions include Biodefense and Biosciences.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.